Affordable Access

Publisher Website

Novel approaches to refractory immune thrombocytopenic purpura

Authors
Journal
Blood Reviews
0268-960X
Publisher
Elsevier
Publication Date
Volume
16
Issue
1
Identifiers
DOI: 10.1054/blre.2001.0178
Disciplines
  • Medicine

Abstract

Abstract Chronic immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune bleeding disorder in which autoantibodies are directed against the individual's own platelets, resulting in increased Fc-mediated platelet destruction by macrophages in the reticuloendothelial system. Although ITP is primarily mediated by IgG autoantibodies, the production of these autoantibodies is regulated by the influence of T lymphocytes and antigen-presenting cells (APC). There is evidence that enhanced T-helper cell/APC interactions in patients with ITP may play an integral role in IgG antiplatelet autoantibody production. New therapies may improve platelet production, decrease platelet antibody production, and decrease monocyte function and/or B-cell and T-cell activities. Understanding these cellular immune responses in ITP may lead to the development of more specific immunoregulatory therapies for the management of this disease.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Long-term outcomes after treatment for refractory...

on New England Journal of Medicin... May 03, 2001

Combination chemotherapy in refractory immune thro...

on New England Journal of Medicin... Apr 29, 1993

Accessory splenectomy for refractory immune thromb...

on American Journal of Hematology June 2011
More articles like this..